ReviewCureus2024
The Use of Platelet-Rich Plasma in De Quervain's Tenosynovitis: A Systematic Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
De Quervain's disease (DQVD) is the stenosing tenosynovitis of tendons in the first extensor compartment of the forearm. It is a common inflammatory condition that is often treated conservatively. While conservative therapy is an effective modality of treatment for a large number of patients suffering from DQVD, some patients do not improve with conservative measures. Many alternative treatment modalities are recognized in the treatment of DQVD. One of the non-surgical treatment strategies that is currently on the rise is platelet-rich plasma (PRP) injections into the first dorsal extensor compartment. It is thought that PRP injections contain growth factors that may provide a regenerative stimulus to tendon healing. Various studies evaluated as a treatment modality for different tendinopathies including DQVD. There remains, however, controversy as to the efficacy of its benefit and efficacy in treating DQVD. This paper is a systematic review of the literature conducted to evaluate the effectiveness of PRP in the treatment of DQVD. The review was conducted in line with PRISMA guidelines for systematic reviews. The review included a systematic search through PubMed, Embase, Cochrane Library, Medline, Amed, and the Web of Sciences, and was supplemented by manual search through other published online resources. The period of search was defined as January 2013 to October 2023, and the search included all studies that evaluated the use of PRP in the treatment of DQVD. A total of 1,029 records were screened; only eight studies met the inclusion criteria and were included in the study. Three randomized clinical trials and five experimental studies were included in the review. A systematic review of the evidence suggested that PRP is a promising and safe alternative to conventional steroid injections in the treatment of De Quervain's tenosynovitis. Further large sample studies are needed prior to the definitive recommendation of PRP as the gold standard for the treatment of De Quervain's tenosynovitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.